Open source impact SalivaDirect originated from an open-source, low-cost COVID-19 diagnostic assay and has evolved into a global diagnostic network and nonprofit. This history signals strong credibility in scalable, cost-conscious testing solutions that can be positioned to potential partners seeking accessible surveillance.

Saliva as standard The organization champions saliva-based testing for equitable respiratory pathogen surveillance, with widespread adoption across CLIA laboratories and international validation in multiple countries. This presents a compelling case for expanding saliva-based testing offerings to new markets or partners seeking less invasive, scalable diagnostics.

Growth signals With over seven million SalivaDirect tests processed nationwide through more than 200 CLIA laboratories and ongoing international validation, there is demonstrated demand and a scalable deployment model that can be leveraged for collaborations, licensing, or expanded services with larger networks.

Funding and sizing Operating as a nonprofit with modest revenue, SalivaDirect may be open to partnerships, sponsored programs, or joint ventures with larger healthcare and biotech entities seeking social impact aligned diagnostics, enabling co-development or grant-backed initiatives.

Tech and reach Current tech stack and digital presence indicate a lightweight, web-enabled operation. There is potential to offer integration-friendly testing workflows, data analytics collaboration, and digital infrastructure partnerships (cloud, analytics, analytics dashboards) to scale deployments for institutional customers.